Bullish
Eli Lilly's stock price reaches $1,255.40, nearing Wall Street's $1,311 target.
Eli Lilly's stock has surged, closing at $1,255.40, just 4.43% below Wall Street's consensus target of $1,311. This rise is attributed to strong second-quarter sales of Mounjaro and Zepbound, which together generated $14.87 billion. Analysts are now focusing on factors like price realization and competition from oral drugs.
Key points
- Eli Lilly's stock price closed at $1,255.40, nearing Wall Street's $1,311 target.
- Second-quarter sales of Mounjaro and Zepbound reached $14.87 billion.
- Analysts emphasize price realization and competition from oral drugs.
Sources
AI-generated from public news sources. Not financial advice.
